Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients

• Status: Terminated
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effects of tegaserod on orocecal and colonic transit in patients over 65 years with chronic constipation.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Collaborators: Temple University; University of Michigan
• Treatments: Tegaserod

Criteria

Inclusion Criteria:

• Male & Females aged 65 and older

• Patients must meet the criteria for chronic idiopathic constipation for at least 12 weeks

• Patients must have had a colonoscopy within the past 5 years

• Patients must pass a balloon expulsion test at screening

• Patients must be able to comply and understand the use of a diary

Exclusion Criteria:

• Patients with a clinically significant medical condition that would interfere with the patient completing the trial

• Patients with loose stools at least once per week

• Patients with IBS

• Known allergies to the same class of drug and/or allergies to eggs

• Patients who require the use of manual maneuvers to have a bowel movement

Other protocol-defined inclusion/exclusion criteria may apply.